Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

NCT06833268 · clinicaltrials.gov ↗

COMPLETED

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

OTHER: No drug

Sponsor

Daiichi Sankyo